Table 4 |
||||||
|
Medication at baseline and at 24 months |
||||||
|
Pure Mania |
Mixed episode |
|||||
|
|
||||||
|
Baseline n = 504 |
Treatment of the episode |
24 Months n = 364 |
Baseline n = 262 |
Treatment of the episode |
24 Months n = 164 |
|
|
|
||||||
|
Antimanic treatment: |
||||||
|
Types of therapy (n,%): |
||||||
|
None |
184 (37%) |
0 |
9 (2%)* |
99 (38%) |
0 |
15 (9%)* |
|
Monotherapy |
191 (38%) |
187 (37%)* |
180 (50%)* |
99 (38%) |
132 (50%)* |
79 (48%)* |
|
Combination |
129 (26%) |
317 (63%)* |
175 (48%)* |
64 (24%) |
130 (50%)* |
70 (43%)* |
|
No. of drugs related to the treatment (n,%): |
||||||
|
None |
184 (37%) |
0 |
9 (2%)* |
99 (38%) |
0 |
15 (9%)* |
|
1 |
191 (38%) |
187 (37%) |
180 (49%)* |
99 (38%) |
132 (50%) |
79 (48%)* |
|
2 |
98 (19%) |
241 (48%) |
145 (40%)* |
41 (16%) |
103 (39%) |
56 (34%)* |
|
3 and + |
31 (6%) |
76 (15%) |
30 (8%)* |
23 (9%) |
27 (10%) |
14 (9%)* |
|
Types of treatment: (n,% Compared to the population) |
||||||
|
Lithium |
64 (13%) |
70 (14%) |
57 (16%)* |
36 (14%) |
40 (15%) |
39 (24%)* |
|
Anticonvulsant |
161 (32%) |
296 (59%) |
187 (51%) |
79 (30%) |
147 (56%) |
72 (44%) |
|
Atypical antipsychotics. |
75 (15%) |
332 (66%) |
212 (58%) |
36 (14%) |
153 (58%) |
85 (52%) |
|
Typical antipsychotics |
144 (29%) |
163 (32%) |
77 (21%) |
75 (29%) |
67 (26%) |
34 (21%) |
|
|
||||||
|
Compliance: |
||||||
|
No prescription |
131 (26%) |
2 (1%)* |
60 (23%) |
5 (3%)* |
||
|
Compliance ≈ 100% |
253 (50%) |
336 (92%) |
147 (56%) |
138 (84%) |
||
|
Compliance ≈ 50% |
80 (16%) |
20 (5%) |
45 (17%) |
17 (10%) |
||
|
No compliance |
36 (7%) |
5 (1%) |
8 (3%) |
3 (2%) |
||
|
|
||||||
|
Course over 24 months: |
||||||
|
Maintains (since baseline) (n,% including LTFup): |
||||||
|
Monotherapy |
. |
. |
84 (45%)* |
27 (21%)* |
||
|
Combination |
101 (32%) |
35 (27%) |
||||
|
The same treatment |
129 (26%)* |
42 (16%)* |
||||
|
Lithium |
33 (47%) |
17 (43%) |
||||
|
Anticonvulsant |
. |
. |
121 (41%)* |
. |
. |
38 (26%)* |
|
Atypical antipsychotics. |
139 (42%) |
48 (31%) |
||||
|
Typical neuroleptics |
34 (21%) |
12 (18%) |
||||
|
No. of changes of treatment: (n,%) |
||||||
|
0 |
. |
. |
62 (17%) |
. |
. |
33 (20%) |
|
1 |
59 (16%) |
29 (18%) |
||||
|
2 |
120 (33%) |
63 (38%) |
||||
|
3 and + |
||||||
|
|
||||||
|
Concomitant treatments: |
||||||
|
Antidepressants |
139 (28%)* |
75 (15%)* |
98 (27%)* |
138 (53%)* |
129 (49%)* |
91 (55%)* |
|
Benzodiazepines |
267 (53%)* |
291 (58%)* |
132 (37%) |
177 (68%)* |
187 (71%)* |
74 (45%) |
|
Anticholinergic drugs |
44 (9%) |
41 (8%) |
21 (6%) |
21 (8%) |
27 (10%) |
10 (6%) |
|
Hypnotics (others) |
156 (31%) |
199 (39%) |
78 (21%) |
92 (35%) |
97 (37%) |
43 (26%) |
|
Types of antidepressant: |
||||||
|
Monotherapy(AD) (n, %): |
134 (96%) |
73 (97%) |
93 (95%) |
135 (98%) |
127 (98%) |
87 (96%) |
|
IRSS |
104 (78%) |
56 (77%) |
74 (80%) |
96 (71%) |
91 (72%) |
65 (75%) |
|
Tricyclic |
25 (19%) |
13 (18%) |
17 (18%) |
21 (16%) |
15 (12%) |
16 (18%) |
|
Others |
5 (4%) |
4 (5%) |
2 (2%) |
18 (13%) |
21 (17%) |
6 (7%) |
|
Combination of AD (n,%): |
5 (4%) |
2 (3%) |
5 (5%) |
3 (2%) |
2 (2%) |
4 (4%) |
|
|
||||||
|
Compliance: the patient nearly always complies with/accepts his/her treatment for bipolar disorders (≈ 100%), half the time (≈ 50%) * = There is a significant difference between the Pure Mania and mixed episode patient groups, threshold α = 0.05. |
||||||
|
Azorin et al. BMC Psychiatry 2009 9:33 doi:10.1186/1471-244X-9-33 |
||||||
